Observational study of neoadjuvant GS chemotherapy for patients with pancreatic cancer

Observational study of neoadjuvant GS chemotherapy for patients with pancreatic cancer - Neoadjuvant GS chemotherapy for pancreatic cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025675

Enrollment

Registered

2017-01-14

Start date

2014-02-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Two cycles of neoadjuvant chemotherapy using Gemcitabine(100mg/m2,day1,day8) and S1(100mg/body or 120mg/body, day1-day14)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)clinical diagnosis of pancreatic cancer 2)no distant metastasis 3)possible macroscopic curative resection 4)treatment naive 5)presence of measurable lesion 6)possible oral intake of S1 7)possible written informed consent 8)age not less than 20

Exclusion criteria

Exclusion criteria: 1)patients with lung fibrosis and/or interstitial pneumoniae 2)unresectable SMA invasion 3)active double cancer 4)active infectious disease 5)creatinine clearance < 30mL/min

Design outcomes

Primary

Measure	Time frame
Safety and efficacy of the neoadjuvant GS chemotherapy	—

Secondary

Measure	Time frame
Changes in tumour size and tumour markers, resection rate and R0 resection rate	—

Countries

Japan

Contacts

Public ContactTaku Aoki

Dokkyo Medical University Hospital Second department of surgery

aoki-2su@dokkyomed.ac.jp0282861111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026